Corporate Business Development Director – Human Genetics
Oxford Nanopore Technologies
Location: Oxford (Hybrid Working)
Travel: Monthly international travel required
About Oxford Nanopore Technologies
Oxford Nanopore Technologies is a leading life sciences company headquartered in Oxford, UK, focused on the development and commercialisation of nanopore sequencing technologies. Our platform enables real-time, accessible, and scalable analysis of DNA and RNA, supporting applications across research, clinical, and industrial settings. We are driven by a mission to make genomic analysis widely available and impactful for human health and beyond.
About the Role
We are seeking an experienced Corporate Business Development Director to take responsibility for partnership activities within the Human Genetics segment. This role sits within the Business Development team, which is focused on building a strong ecosystem of strategic partnerships to accelerate the adoption of nanopore sequencing and generate long-term revenue growth.
You will lead the development of partnerships with organisations aiming to commercialise applications of nanopore sequencing across prioritised clinical and industrial markets.
Key Responsibilities
What We’re Looking For
This role is well suited to someone who thrives in a collaborative, cross-functional environment and is motivated to build impactful partnerships that advance genomic technologies in human health.
Apply now to join Oxford Nanopore Technologies and help shape the future of molecular sensing and genomic innovation.
Please note that no terminology in this advert is intended to discriminate on the grounds of a person's gender, marital status, race, religion, colour, age, disability or sexual orientation. Every candidate will be assessed only in accordance with their merits, qualifications and abilities to perform the duties of the job.
#LI-LH1
#LI-hybrid
Oxford Nanopore Technologies: Our goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. With a thriving culture of ambition and strong innovation goals, Oxford Nanopore is a UK headquartered company with global operations and customers in more than 125 countries.
Our goal is to enable the analysis of anything, anywhere, by anyone.
We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data.
We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society.
Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide.
Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
